Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency.
暂无分享,去创建一个
K. Ohe | Y. Nakanishi | M. Nomura | Y. Ogawa | Shimpei Iwata | N. Wada | Kenji Ashida | R. Sakamoto | M. Ogata | Y. Matsuda | Seiichi Yano | C. Sakaguchi | Kengo Maruyama | S. Sakamoto | Munehiko Ikeda | Shoko Akasu
[1] H. Uchi,et al. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. , 2019, Current oncology.
[2] M. Kanai,et al. Genetic and phenotypic landscape of the major histocompatibilty complex region in the Japanese population , 2019, Nature Genetics.
[3] K. Ohe,et al. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma , 2019, The American journal of case reports.
[4] F. Hodi,et al. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.
[5] T. Pawlik,et al. Histopathological and immunophenotypic features of ipilimumab‐associated colitis compared to ulcerative colitis , 2018, Journal of internal medicine.
[6] A. Pontecorvi,et al. Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients , 2018, Clinical endocrinology.
[7] Peng-fei Wang,et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis , 2017, Front. Pharmacol..
[8] W. Barry,et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[9] F. Hodi,et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.
[10] H. Gogas,et al. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy , 2017, Cancer investigation.
[11] Andreas Handel,et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells , 2017, Nature.
[12] K. Ohnaka,et al. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab , 2017, Japanese journal of clinical oncology.
[13] M. Cosottini,et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. , 2016, The American journal of pathology.
[14] A. Sugawara,et al. Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [Opinion]. , 2016, Endocrine journal.
[15] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[16] L. Liau,et al. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. , 2015, The Journal of clinical endocrinology and metabolism.
[17] D. Middleton,et al. Determination of HLA‐A, ‐C, ‐B, ‐DRB1 allele and haplotype frequency in Japanese population based on family study , 2015, Tissue antigens.
[18] G. Chrousos,et al. Adrenal insufficiency , 2014, The Lancet.
[19] J. Wolchok,et al. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.
[20] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[21] O. Karadag,et al. Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey , 2012, Arthritis Research & Therapy.
[22] C. Punt,et al. PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer , 2012, Journal of immunotherapy.
[23] Simon C. Potter,et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.
[24] A. Imagawa,et al. Class II HLA genotype in fulminant type 1 diabetes: A nationwide survey with reference to glutamic acid decarboxylase antibodies , 2011, Journal of diabetes investigation.
[25] D. Goodman,et al. Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma , 2010 .
[26] S. Holdsworth,et al. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. , 2009, Journal of the American Society of Nephrology : JASN.
[27] T. Hibi,et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease , 2008, Gut.
[28] F. Mihara,et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. , 2005, Brain : a journal of neurology.
[29] A. Rees,et al. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. , 1999, Kidney international.
[30] S. Makino,et al. Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. , 1997, Endocrine journal.
[31] H. Inoko,et al. Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. , 1993, Human immunology.
[32] J. Säfwenberg,et al. Influence of the HLA-DR4 antigen and iodine status on the development of autoimmune postpartum thyroiditis. , 1985, The Journal of clinical endocrinology and metabolism.
[33] R. Jansson,et al. INFLUENCE OF HLA-DR4 ON THE DEVELOPMENT OF AUTOIMMUNE POSTPARTUM THYROIDITIS1 , 1985 .